{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ATTACC","nct_id":"NCT04972110","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=attacc-nct04972110. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ATTACC","arms":[{"description":"Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with olaparib","label":"Phase Ib Dose Escalation","type":"EXPERIMENTAL"},{"description":"Expansion cohort with RP-3500 (camonsertib) + niraparib and/or Expansion cohort RP-3500 (camonsertib) + olaparib","label":"Phase 2 Expansion Cohorts","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-11-13","type":"ACTUAL"},"conditions":["Advanced Solid Tumor, Adult"],"enrollment":{"count":156,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"RP-3500 (camonsertib)","otherNames":["niraparib","olaparib"],"type":"DRUG"}],"last_update":"2025-10-30","lead_sponsor":"Repare Therapeutics","official_title":"Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-11-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors","timeFrame":"Start of treatment to 30 days post last dose, up to 23.7 months"},{"measure":"Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid Tumors","timeFrame":"During 21 days (one cycle) from the initiation of the study treatment"}],"references":[{"citation":"Silverman IM, Schonhoft JD, Herzberg B, Yablonovitch A, Lagow E, Fiaux PC, Safabakhsh P, Sethuraman S, Ulanet D, Yang J, Kim I, Basciano P, Cecchini M, Lee E, Lheureux S, Fontana E, Carneiro BA, Reis-Filho JS, Yap TA, Zinda M, Rosen EY, Rimkunas V. Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors. Clin Cancer Res. 2025 Oct 1;31(19):4136-4149. doi: 10.1158/1078-0432.CCR-25-1248.","pmid":"40705098","type":"DERIVED"}],"start_date":{"date":"2021-07-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04972110"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/attacc-nct04972110"}